Logo-ipp

Immunopathol Persa. 2019;5(2): e15. doi: 10.15171/ipp.2019.15

Original

Rituximab versus cyclophosphamide for the treatment of children with steroid resistance nephrotic syndrome; a clinical trial study

Mohsen Akhavan Sepahi 1,2 ORCID, Najmeh Farahani 2, Mohammad Reza Razavi 1,2 * ORCID, Hossein Heydari 2,3 ORCID, Shahram Arsang-Jang 4 ORCID

Cited by CrossRef: 1

1- Widiasta A, Wahyudi K, Nugrahapraja H, Sribudiani Y, Rachmadi D. The Unique Difference Between Serum Level of Soluble Urokinase Plasminogen Activator Receptor (suPAR) in Steroid-Resistant Nephrotic Syndrome Children Treated with an Alkylating Agent and Calcineurin Inhibitors. J Compr Ped. 2021;12(2) [Crossref]